Furthermore, MCT-anti-miR-146a rats show lower levels of the cardiac dysfunction markers BNP and COL3A1 compared to MCT-vehicle rats (Figure 7A and Figure 7B, respectively), confirming miR-146a’s involvement in PAH pathophysiology and supporting the potential therapeutic benefits of miR-146a inhibition in mitigating RV failure and PAH progression. Here, NPPB is linked to pulmonary arterial hypertension.